Alfavir Tablet 25mg contains tenofovir, a potent antiviral medication used in the treatment of human immunodeficiency virus (HIV) infection and hepatitis B virus (HBV) infection. This nucleotide reverse transcriptase inhibitor (NRTI) is an essential component of antiretroviral therapy (ART) for individuals living with HIV.
Uses
- Treatment of HIV-1 infection in adults and pediatric patients
- Treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.
- Part of combination antiretroviral therapy regimens for managing HIV infection
Benefit
- Suppresses the replication and spread of HIV
- Helps reduce viral load and increase CD4 cell counts
- Contributes to the overall management of HIV infection
Dosage
- Dosage may vary based on individual factors, such as age, weight, and concomitant medications
- Typically taken once daily, in combination with other antiretroviral drugs
- Follow your healthcare provider’s instructions carefully
Mechanism of Action
Tenofovir, the active ingredient in Alfavir Tablet 25mg, is an NRTI that inhibits the activity of HIV reverse transcriptase, an enzyme essential for viral replication. By blocking this enzyme, tenofovir prevents the virus from replicating and spreading further within the body.
Side Effects
- Common side effects may include nausea, diarrhea, vomiting, and headache
- Rare but serious side effects may include lactic acidosis, kidney problems, and bone density loss
Warning
- Use with caution in patients with kidney disease or bone disorders
- May interact with other medications, so inform your healthcare provider about all medications you are taking
- Avoid consuming alcohol or other hepatotoxic substances while taking Alfavir
Important Information
- Alfavir Tablet 25mg should be taken as part of a comprehensive HIV treatment regimen
- Strict adherence to the prescribed dosing schedule is crucial for optimal efficacy
- Regular monitoring of viral load, CD4 cell counts, and potential side effects is recommended
Reviews
There are no reviews yet.